New drug cocktail aims to fight advanced colon cancer

NCT ID NCT07204574

Recruiting now Disease control Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tests an experimental drug called HCB101 alongside standard treatments (bevacizumab, cetuximab, and chemotherapy) in 40 people with advanced or metastatic colorectal cancer. The goal is to see if the combination is safe and shows signs of shrinking tumors. Participants receive weekly infusions of HCB101 plus standard drugs every two weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HCB101 (an experimental drug) combined with bevacizumab, cetuximab, and chemotherapy (FOLFOX or FOLFIRI)
What this could lead to: If successful, this could point toward a new combination treatment that helps control advanced colorectal cancer for longer.
What could go wrong: This is an early-phase trial with only 40 people, so results may not apply widely. The combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRC

Contacts and locations

Locations

Linkou Chang-Gung Memorial Hospital
RECRUITING

Taoyuan, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.